Early Development Of Genentech News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Interline Therapeutics Raises $92M in Funding
The round was led by Foresite Capital and ARCH Venture Partners.
The company intends to use the funds to expand the research platform and advance six preclinical therapeutic programs.
Co-founded by CEO Zachary Sweeney, Interline Therapeutics is a Foresite Labs incubated company that focuses on systematically elucidating protein communities to define molecular mechanisms of disease.
The company uses genomics, proteomics, structural biology and computational chemistry to systematically map and modulate protein communities. Interline Therapeutics is leveraging recent advancements in these technologies, as well as collaborations with academic groups, to develop a precision medicine platform focused on three essential areas: ....

University Of California San Francisco , United States , San Francisco , David Tully , Wade Harper , Nick Galli , Zachary Sweeney , Mario Cardozo , Mike Varney , John Chodera , Don Kirkpatrick , Brenda Schulman , Nevanj Krogan , Early Development Of Genentech , Sloan Kettering Institute , Max Planck Institute Of Biochemistry , Harvard Medical School , Memorial Sloan Kettering Cancer Center , Interline Therapeutics , Foresite Capital , Foresite Labs , Chief Operating Officer , Chief Technology Officer , Vice President Computational Chemistry , Anj Saha , Vice President Discovery Pharmacology ,